These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The role of cancer stem cells in the modulation of anti-tumor immune responses. Maccalli C; Rasul KI; Elawad M; Ferrone S Semin Cancer Biol; 2018 Dec; 53():189-200. PubMed ID: 30261276 [TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860 [TBL] [Abstract][Full Text] [Related]
8. Emerging role of natural products in cancer immunotherapy. Dong S; Guo X; Han F; He Z; Wang Y Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162 [TBL] [Abstract][Full Text] [Related]
9. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913 [TBL] [Abstract][Full Text] [Related]
10. The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model. Bellamkonda K; Chandrashekar NK; Osman J; Selvanesan BC; Savari S; Sjölander A BMC Cancer; 2016 Jul; 16():425. PubMed ID: 27388564 [TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Adachi K; Tamada K Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182 [TBL] [Abstract][Full Text] [Related]
13. [The biological rationale for immunotherapy in cancer]. Benzaquen J; Marquette CH; Glaichenhaus N; Leroy S; Hofman P; Ilié M Rev Mal Respir; 2018 Feb; 35(2):206-222. PubMed ID: 29428191 [TBL] [Abstract][Full Text] [Related]
14. NK cell-based therapeutics for lung cancer. Pockley AG; Vaupel P; Multhoff G Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156 [No Abstract] [Full Text] [Related]
15. Tim-3 and its role in regulating anti-tumor immunity. Das M; Zhu C; Kuchroo VK Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697 [TBL] [Abstract][Full Text] [Related]
16. Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. Sabbatino F; Wang Y; Wang X; Schwab JH; Ferrone S; Ferrone CR Semin Oncol; 2014 Oct; 41(5):685-99. PubMed ID: 25440613 [TBL] [Abstract][Full Text] [Related]
17. Aldehyde Dehydrogenese-1 High Cancer Stem-like Cells/Cancer-initiating Cells Escape from Cytotoxic T Lymphocytes due to Lower Expression of Human Leukocyte Antigen Class 1. Shirosaki T; Kawai N; Ebihara Y; Murai A; Kubo T; Morita R; Murata K; Kanaseki T; Tsukahara T; Shichinohe T; Hirohashi Y; Hirano S; Torigoe T Anticancer Res; 2024 May; 44(5):1877-1883. PubMed ID: 38677758 [TBL] [Abstract][Full Text] [Related]
18. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. Kumar A; Chamoto K; Chowdhury PS; Honjo T Elife; 2020 Mar; 9():. PubMed ID: 32122466 [TBL] [Abstract][Full Text] [Related]
19. Targeting cancer initiating cells by promoting cell differentiation and restoring chemosensitivity via dual inactivation of STAT3 and src activity using an active component of antrodia cinnamomea mycelia. Chang CW; Chen YS; Chen CC; Chan IO; Chen CC; Sheu SJ; Lin TW; Chou SH; Liu CJ; Lee TC; Lo JF Oncotarget; 2016 Nov; 7(45):73016-73031. PubMed ID: 27682875 [TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]